Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
Arthritis & Rheumatism2003Vol. 48(1), pp. 35–45
Citations Over TimeTop 1% of 2003 papers
Michael E. Weinblatt, Edward Keystone, Daniel E. Furst, Larry W. Moreland, Michael H. Weisman, C. Birbara, Leah A. Teoh, Steven Fischkoff, Elliot Chartash
Abstract
The addition of adalimumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-term MTX therapy in patients with active RA provided significant, rapid, and sustained improvement in disease activity over 24 weeks compared with MTX plus placebo.
Related Papers
- Adalimumab for Crohn's disease in New Zealand--a prospective multicentre experience.(2014)
- → THU0211 Six months after treatment discontinuation tnf is still in complex with adalimumab(2018)1 cited
- → The Effect of Adalimumab on Refractory Uveitis(2020)1 cited
- → FRI0165 A prediction tool for drug monitoring of adalimumab in rheumatoid arthritis.(2013)
- 강직성 척추염 환자에서 Adalimumab 치료 후 관찰된 천장관절염의 회복 1예 Running title: 강직성 척추염에서 Adalimumab 치료와 천장관절염의 회복(2012)